ANTI-AGEING A Gene expression
2.0 1.5 1.0 0.5 0.0
Control
strongest facial expression (frowning) were compared to total surface of the measured area.
Results SCBE upregulates SIRT6 and FOXO3 gene expression To determine the capacity of SCBE to increase the expression of the longevity genes SIRT6 and FOXO3, NHEK were treated with SCBE for 24 hours. As shown in Figure 2, SCBE significantly increased SIRT6 expression by 181% compared to untreated cells. FOXO3 expression increased by 104% in
keratinocytes treated with SCBE. Thus, SCBE significantly increases the expression of these two longevity genes, which themselves control various cellular mechanisms involved in healthy skin life expectancy.
SCBE upregulates LC3 and LAMP2 gene expression and protein synthesis In order to determine the ability of SCBE to stimulate gene and protein expression of these autophagy markers, NHEK were treated with SCBE for 24 hours. SCBE increased the transcriptional expression of LAMP2 (Figure 3A) and LC3 (Figure 4A) genes by 80% and
A Gene expression
2.0 1.5 1.0 0.5 0.0
Control
+44% *
+80% **
B
Protein expression +25%
140 120 100 80 60 40 20 0
SCBE Figure 3: Relative expression of LAMP2 in SCBE-treated NHEK versus control; *p<0.05, **p<0.01
44% respectively versus control. These results were then validated at protein
level, as SCBE increased protein detection of LAMP2 and LC3 by 25% (Figure 3B) and 26% (Figure 4B) respectively. Schisandrin alone applied as a positive control resulted in a significant increase of 18% in LAMP2 and 19% in LC3: it therefore participates in the activity of SCBE on autophagy.
SCBE upregulates mitochondria activity Mitochondrial activity from NHEK was measured using a fluorescent probe (MitoTracker®) capable of specifically penetrating active mitochondria. Fluorescence, proportional to mitochondrial activity, increased by 55% with SCBE and shisandrin alone as compared to the untreated control (Figure 5), demonstrating the involvement of this molecule in the positive action of SCBE on mitochondrial activity.
SCBE increases skin dynamic elasticity As described in the Materials and methods section, the elastic deformation of the face was measured at D0 and D28 after daily application of SCBE 1% and placebo in a split-
B
face manner. An air blow was applied on the lower part of the face, and the recovery time of the skin was measured in milliseconds thanks to a high-speed camera. The faster the skin returns to its original
states, the more elastic it is. After 28 days of application, as shown in
Figure 6, SCBE1% induced a 16.8% decrease regarding recovery time after blowing the lower part of the face. The air blown experiment shows that SCBE1% significantly increases skin elasticity and prevents sagging.
SCBE reduces existing wrinkles After daily application of SCBE 1% during 28 days, wrinkle number was counted on crow’s feet area with an AEVA-HE 3D measurement technic at D0, D14 and D28. SCBE shows a 4.1% decrease in skin roughness and a 10.8% decrease in wrinkle counting compared to placebo (Figure 7).
SCBE prevents wrinkle formation As previously described, skin features density was measured on crow’s feet area with an AEVA-HE 3D measurement technic at D0 and D28. A dynamic protocol was used where
140 120 100 80 60 40 20 0
SCBE Figure 4: Relative expression of LC3 in SCBE-treated NHEK versus control; *p<0.05, ***p<0.001
www.personalcaremagazine.com November 2024 PERSONAL CARE Control
Protein expression +26%
*** * Control ** *
59
SCBE
Schisandrin
SCBE
Schisandrin
Expression relative LAMP2A vs NT (2-ΔΔCT)
Expression relative LAMP2A vs NT (2ΔΔCT
)
Protein relative LC3 vs control (%)
Protein relative LAMP2A vs control (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100
